Unintended Effects of Public Reporting of PCI Mortality

After New York State's exclusion of cardiogenic shock from the required public reporting of outcomes after percutaneous coronary intervention, more patients underwent the intervention.

Public reporting of mortality after percutaneous coronary intervention (PCI), first required in New York State (NY), was intended to build public trust and improve care. Concerns later arose that public reporting could lead operators to inappropriately avoid risks in higher-risk patients; therefore, NY excluded outcomes on patients with acute myocardial infarction (AMI) and cardiogenic shock from public reporting in 2006. The current investigators examined outcomes in NY before and after the exclusion and in four states with no exclusion or no public-reporting mandate; analyses involved 45,977 patients with AMI and shock (25% in NY) and compared two periods, 2002–2005 (NY's preexclusion era) and 2006–2012 (postexclusion).

In NY, the rate of …

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)